Navigation Links
Ben-Gurion U. and Fox Chase Cancer Center awarded NIH measles grant
Date:4/18/2013

PHILADELPHIA April 18, 2013 American Associates, Ben-Gurion University of the Negev (AABGU) announces that Ben-Gurion University of the Negev (BGU) and Fox Chase Cancer Center (FCCC) in Philadelphia have received a two-year National Institutes of Health (NIH) research grant to observe "the role of host encoded microRNAs in the maintenance of the measles virus persistent state."

Many viruses are known to persist in their target cells and establish chronic infection, long after resolution of their acute phase. A thorough understanding of this interplay between viruses and their host may offer insight into the mechanistic basis of human infectious diseases.

This research collaboration is part of an ongoing agreement between BGU and FCCC to support and facilitate scientific and clinical exchanges, as well as to encourage collaborations and joint research between scientists and physicians. Fox Chase and Ben-Gurion formalized their relationship in 2008, but it actually began in 2003 as a partnership spearheaded by AABGU's National Vice President Alton I. Sutnick.

Sutnick, founder of the Health Sciences and Academic Affiliations Committee of AABGU's Mid-Atlantic Region, is a physician and former dean of the Medical College of Pennsylvania (now the Drexel University School of Medicine). Through this partnership, he sought to explore the genetic risks of cancer and incorporate these factors into clinical practice across cultural settings.

"Thanks to Dr. Sutnick and AABGU's Philadelphia chapter, BGU has a longstanding research partnership with Fox Chase that has greatly contributed to medical science," explains Doron Krakow, AABGU executive vice president. "It is a great accomplishment to receive this NIH grant and we look forward to their findings."


'/>"/>

Contact: Andrew Lavin
andrewlavin@alavin.com
516-944-4486
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Page: 1

Related biology news :

1. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
2. Sleep deprivation may reduce risk of PTSD according to Ben-Gurion U. researchers
3. Ben-Gurion University of the Negev receives $450,000 grant to conduct oil and natural gas research
4. Preeclampsia poses a significant long-term health risk according to new research from Ben-Gurion U.
5. Ben-Gurion University team in prestigious DARPA Robotics Challenge to develop disaster response robot
6. Ben-Gurion U. establishes stem cell research fund in honor of inventor Jordan Baruch
7. Ben-Gurion U. researchers and Teva Pharmaceutical Industries Ltd. develop psoriasis drug
8. Obama calls Ben-Gurion U. brain research a great idea
9. Navigating the Patent Minefield of Embryonic Stem Cell Product Development; Free Kindle Fire Tablet and Research Database with Purchase
10. Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed
11. Embryonic development protein active in cancer growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... of the future.  1,000 participants were simply asked which office ... which we may consider standard issue.  Insights on what ... were also gathered from futurists and industry leaders including ... James Canton .  Some of these ...
(Date:1/11/2017)... N.J. , Jan. 11, 2017  Michael Johnson, co-founder of ... Venture Capital Group, Inc., has been named to the elite "Forbes ... 27,  was one of 600 people in 20 fields nationwide to ... percent of the 15,000 applicants were selected. ... He is currently a PhD candidate at ...
(Date:1/6/2017)...  Delta ID Inc., a leader in consumer-grade iris ... at CES® 2017. Delta ID has collaborated with Gentex ... use of iris scanning as a secure, reliable and ... a car, and as a way to elevate the ... Delta ID and Gentex will demonstrate (booth #7326 LVCC) ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, ... a fully 21 CFR Part 11-compliant email client designed to provide product vigilance ...
(Date:1/19/2017)... 2017 AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: ... aquaculture and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... the listing of its common shares on the NASDAQ ... "AquaBounty,s listing on NASDAQ represents an important ... to the U.S. markets as we advance plans for ...
(Date:1/19/2017)... NY (PRWEB) , ... January 19, 2017 , ... FireflySci ... an exponential rate. The tremendous growth is accounted to two main factors. ... table and the expanding network of vendors supplying FireflySci products all around the world. ...
(Date:1/19/2017)... Jan. 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ... immune therapies for operable and inoperable solid tumor cancers, ... Technical Officer of NW Bio, will present at the ... at the Hyatt Regency Hotel in Miami, ... the session entitled "New Therapeutic Approaches – Expanding the ...
Breaking Biology Technology: